{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:59:50Z","timestamp":1790200790730,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U01DA056240"],"award-info":[{"award-number":["U01DA056240"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U01DA045366"],"award-info":[{"award-number":["U01DA045366"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00213-025-06959-9","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T05:24:15Z","timestamp":1765517055000},"page":"2131-2141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison between a chimeric anti-methamphetamine monoclonal antibody and humanized antibodies on pharmacological effects of methamphetamine"],"prefix":"10.1007","volume":"243","author":[{"given":"Michael Dale","family":"Berquist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gunnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Brooks","family":"Gentry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misty Ward","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"6959_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108060","volume":"212","author":"P AshaRani","year":"2020","unstructured":"AshaRani P, Hombali A, Seow E, Ong WJ, Tan JH, Subramaniam M (2020) Non-pharmacological interventions for methamphetamine use disorder: a systematic review. Drug Alcohol Depend 212:108060. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108060","journal-title":"Drug Alcohol Depend"},{"key":"6959_CR2","unstructured":"Association AP (2022) Diagnostic and Statistical Manual of Mental Disorders (5th, text rev ed)"},{"key":"6959_CR3","unstructured":"Beyfortus\u00ae(nirsevimab-alip). Prescribing Information.\u00a0Sanofi (2023)\u00a0(n.d.).\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761328s000lbl.pdf"},{"issue":"12","key":"6959_CR4","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1021\/bc100261d","volume":"21","author":"CA Boswell","year":"2010","unstructured":"Boswell CA, Tesar DB, Mukhyala K, Theil F-P, Fielder PJ, Khawli LA (2010) Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 21(12):2153\u20132163. https:\/\/doi.org\/10.1021\/bc100261d","journal-title":"Bioconjug Chem"},{"key":"6959_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1283120","volume":"14","author":"T Brady","year":"2023","unstructured":"Brady T, Cayatte C, Roe TL, Speer SD, Ji H, Machiesky L, Zhang T, Wilkins D, Tuffy KM, Kelly EJ (2023) Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. Front Immunol 14:1283120. https:\/\/doi.org\/10.3389\/fimmu.2023.1283120","journal-title":"Front Immunol"},{"key":"6959_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.drugalcdep.2014.02.702","volume":"139","author":"M-L Brecht","year":"2014","unstructured":"Brecht M-L, Herbeck D (2014) Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors. Drug Alcohol Depend 139:18\u201325. https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.02.702","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"6959_CR7","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1111\/add.14755","volume":"114","author":"B Chan","year":"2019","unstructured":"Chan B, Freeman M, Kondo K, Ayers C, Montgomery J, Paynter R, Kansagara D (2019) Pharmacotherapy for methamphetamine\/amphetamine use disorder\u2014a systematic review and meta-analysis. Addiction 114(12):2122\u20132136. https:\/\/doi.org\/10.1111\/add.14755","journal-title":"Addiction"},{"issue":"12","key":"6959_CR8","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1111\/add.13897","volume":"112","author":"S Darke","year":"2017","unstructured":"Darke S, Kaye S, Duflou J (2017) Rates, characteristics and circumstances of methamphetamine-related death in Australia: a national 7\u2010year study. Addiction 112(12):2191\u20132201. https:\/\/doi.org\/10.1111\/add.13897","journal-title":"Addiction"},{"issue":"3","key":"6959_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/1556-4029.13620","volume":"63","author":"S Darke","year":"2018","unstructured":"Darke S, Lappin J, Kaye S, Duflou J (2018) Clinical characteristics of fatal methamphetamine-related stroke: a national study. J Forensic Sci 63(3):735\u2013739. https:\/\/doi.org\/10.1111\/1556-4029.13620","journal-title":"J Forensic Sci"},{"issue":"5","key":"6959_CR10","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/1556-4029.14056","volume":"64","author":"S Darke","year":"2019","unstructured":"Darke S, Duflou J, Kaye S, Farrell M, Lappin J (2019) Psychostimulant use and fatal stroke in young adults. J Forensic Sci 64(5):1421\u20131426. https:\/\/doi.org\/10.1111\/1556-4029.14056","journal-title":"J Forensic Sci"},{"issue":"5","key":"6959_CR11","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1111\/1556-4029.13710","volume":"63","author":"S Darke","year":"2018","unstructured":"Darke S, Duflou J, Lappin J, Kaye S (2018) Clinical and autopsy characteristics of fatal methamphetamine toxicity in Australia. J Forensic Sci 63(5):1466\u20131471. https:\/\/doi.org\/10.1111\/1556-4029.13710","journal-title":"J Forensic Sci"},{"issue":"3","key":"6959_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/09595230801923702","volume":"27","author":"S Darke","year":"2008","unstructured":"Darke S, Kaye S, McKetin R, Duflou J (2008) Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 27(3):253\u2013262. https:\/\/doi.org\/10.1080\/09595230801923702","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"6959_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2152526","volume":"15","author":"A Dippel","year":"2023","unstructured":"Dippel A, Gallegos A, Aleti V, Barnes A, Chen X, Christian E, Delmar J, Du Q, Esfandiary R, Farmer E, Garcia A, Li Q, Lin J, Liu W, Machiesky L, Mody N, Parupudi A, Prophet M, Rickert K, Rosenthal Kim, Ren Song, Shandilya Harini, Varkey Reena, Wons Kevin, Wu Yuling, Loo Yueh-Ming, Esser Mark T., Kallewaard Nicole L., Rajan Sarav, Damschroder Melissa, Xu Weichen, Kaplan G (2023) Developability profiling of a panel of Fc engineered SARS-CoV-2 neutralizing antibodies. MAbs 15(1):2152526. https:\/\/doi.org\/10.1080\/19420862.2022.2152526","journal-title":"MAbs"},{"issue":"9","key":"6959_CR14","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1177\/1352458517720044","volume":"24","author":"N Dunn","year":"2017","unstructured":"Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, Piehl F, Fogdell-Hahn A (2017) Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler J 24(9):1224\u20131233. https:\/\/doi.org\/10.1177\/1352458517720044","journal-title":"Mult Scler J"},{"issue":"7","key":"6959_CR15","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","volume":"33","author":"AA Fasanmade","year":"2011","unstructured":"Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM (2011) Pharmacokinetic properties of infliximab in children and adults with Crohn\u2019s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 33(7):946\u2013964. https:\/\/doi.org\/10.1016\/j.clinthera.2011.06.002","journal-title":"Clin Ther"},{"issue":"9","key":"6959_CR16","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1080\/21645515.2016.1179407","volume":"12","author":"MD Hambuchen","year":"2016","unstructured":"Hambuchen MD, R\u00fcedi-Bettschen D, Gunnell MG, Hendrickson H, Owens SM (2016) Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies. Hum Vaccin Immunother 12(9):2240\u20132248. https:\/\/doi.org\/10.1080\/21645515.2016.1179407","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"6959_CR17","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","volume":"78","author":"B Han","year":"2021","unstructured":"Han B, Compton WM, Jones CM, Einstein EB, Volkow ND (2021) Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults. JAMA Psychiatr 78(12):1329\u20131342. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.2588","journal-title":"JAMA Psychiatr"},{"issue":"2","key":"6959_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40259-023-00641-2","volume":"38","author":"CT Harris","year":"2024","unstructured":"Harris CT, Cohen S (2024) Reducing immunogenicity by design: approaches to minimize immunogenicity of monoclonal antibodies. BioDrugs 38(2):205\u2013226. https:\/\/doi.org\/10.1007\/s40259-023-00641-2","journal-title":"BioDrugs"},{"issue":"6","key":"6959_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.4161\/mabs.22189","volume":"4","author":"I H\u00f6tzel","year":"2012","unstructured":"H\u00f6tzel I, Theil F-P, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, Fielder P, Carter PJ, Kelley RF (2012) A strategy for risk mitigation of antibodies with fast clearance. MAbs 4(6):753\u2013760. https:\/\/doi.org\/10.4161\/mabs.22189","journal-title":"MAbs"},{"issue":"1","key":"6959_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","volume":"36","author":"WYK Hwang","year":"2005","unstructured":"Hwang WYK, Foote J (2005) Immunogenicity of engineered antibodies. Methods 36(1):3\u201310. https:\/\/doi.org\/10.1016\/j.ymeth.2005.01.001","journal-title":"Methods"},{"issue":"5","key":"6959_CR21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/protein\/gzq009","volume":"23","author":"T Igawa","year":"2010","unstructured":"Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, Hattori K (2010) Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 23(5):385\u2013392. https:\/\/doi.org\/10.1093\/protein\/gzq009","journal-title":"Protein Eng Des Sel"},{"issue":"8","key":"6959_CR22","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1360-0443.2008.02231.x","volume":"103","author":"S Kaye","year":"2008","unstructured":"Kaye S, Darke S, Duflou J, McKetin R (2008) Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addiction 103(8):1353\u20131360. https:\/\/doi.org\/10.1111\/j.1360-0443.2008.02231.x","journal-title":"Addiction"},{"issue":"20","key":"6959_CR23","doi-asserted-by":"publisher","first-page":"8951","DOI":"10.1523\/jneurosci.22-20-08951.2002","volume":"22","author":"KE Larsen","year":"2002","unstructured":"Larsen KE, Fon EA, Hastings TG, Edwards RH, Sulzer D (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci 22(20):8951\u20138960. https:\/\/doi.org\/10.1523\/jneurosci.22-20-08951.2002","journal-title":"J Neurosci"},{"issue":"11","key":"6959_CR24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v110.11.2371.2371","volume":"110","author":"J Li","year":"2007","unstructured":"Li J, Levi M, Charoin J-E, Frey N, Kheoh T, Ren S, Woo M, Joshi A, Valente N, Jumbe N, Shasha (2007) Rituximab exhibits a long half-life based on a population pharmacokinetic analysis in Non-Hodgkin\u2019s Lymphoma (NHL) patients. Blood 110(11):2371. https:\/\/doi.org\/10.1182\/blood.v110.11.2371.2371","journal-title":"Blood"},{"issue":"2","key":"6959_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1440-1819.2003.01218.x","volume":"58","author":"S-K Lin","year":"2004","unstructured":"Lin S-K, Ball D, Hsiao C-C, Chiang Y, Ree S, Chen C (2004) Psychiatric comorbidity and gender differences of persons incarcerated for methamphetamine abuse in Taiwan. Psychiatry Clin Neurosci 58(2):206\u2013212. https:\/\/doi.org\/10.1111\/j.1440-1819.2003.01218.x","journal-title":"Psychiatry Clin Neurosci"},{"issue":"11","key":"6959_CR26","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/acem.14094","volume":"27","author":"CE Murphy","year":"2020","unstructured":"Murphy CE, Wang RC, Coralic Z, Lai AR, Raven M (2020) Association between methamphetamine use and psychiatric hospitalization, chemical restraint, and emergency department length of stay. Acad Emerg Med 27(11):1116\u20131125. https:\/\/doi.org\/10.1111\/acem.14094","journal-title":"Acad Emerg Med"},{"key":"6959_CR27","doi-asserted-by":"crossref","unstructured":"Nicosia N, Pacula RL, Kilmer B, Lundberg R, Chiesa J (2009)\u00a0The Economic Cost of Methamphetamine Use in the United States, 2005. Santa Monica, CA: RAND Corporation, 2009. https:\/\/www.rand.org\/pubs\/monographs\/MG829.html","DOI":"10.7249\/MG829"},{"issue":"8","key":"6959_CR28","doi-asserted-by":"publisher","first-page":"892","DOI":"10.2174\/187152711799219370","volume":"10","author":"SM Owens","year":"2011","unstructured":"Owens SM, Atchley WT, Hambuchen MD, Peterson EC, Gentry WB (2011) Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. CNS & Neurological Disorders - Drug Targets 10(8):892\u2013898. https:\/\/doi.org\/10.2174\/187152711799219370","journal-title":"CNS & Neurological Disorders - Drug Targets"},{"issue":"1","key":"6959_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::aid-syn5>3.0.co;2-3","volume":"39","author":"RB Rothman","year":"2001","unstructured":"Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39(1):32\u201341. https:\/\/doi.org\/10.1002\/1098-2396(20010101)39:1%3C;32::aid-syn5%3E;3.0.co;2-3","journal-title":"Synapse"},{"key":"6959_CR30","unstructured":"SAMHSA (2022)\u00a0Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https:\/\/www.samhsa.gov\/data\/report\/2021-nsduh-annual-national-report"},{"issue":"52","key":"6959_CR31","doi-asserted-by":"publisher","first-page":"18601","DOI":"10.1073\/pnas.1421779112","volume":"111","author":"VK Sharma","year":"2014","unstructured":"Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I, Zhou JZ, Dill KA, Swartz TE (2014) In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proc Natl Acad Sci U S A 111(52):18601\u201318606. https:\/\/doi.org\/10.1073\/pnas.1421779112","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"6959_CR32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40263-020-00711-x","volume":"34","author":"KJ Siefried","year":"2020","unstructured":"Siefried KJ, Acheson LS, Lintzeris N, Ezard N (2020) Pharmacological treatment of methamphetamine\/amphetamine dependence: a systematic review. CNS Drugs 34(4):337\u2013365. https:\/\/doi.org\/10.1007\/s40263-020-00711-x","journal-title":"CNS Drugs"},{"issue":"2","key":"6959_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4161\/mabs.27620","volume":"6","author":"MW Stevens","year":"2014","unstructured":"Stevens MW, Tawney RL, West CM, Kight AD, Henry RL, Owens SM, Gentry WB (2014) Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use. MAbs 6(2):547\u2013555. https:\/\/doi.org\/10.4161\/mabs.27620","journal-title":"MAbs"},{"issue":"6","key":"6959_CR34","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.4161\/19420862.2014.976431","volume":"6","author":"MW Stevens","year":"2014","unstructured":"Stevens MW, Henry RL, Owens SM, Schutz R, Gentry WB (2014) First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. MAbs 6(6):1649\u20131656. https:\/\/doi.org\/10.4161\/19420862.2014.976431","journal-title":"MAbs"},{"issue":"14","key":"6959_CR35","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/0006-2952(80)90493-1","volume":"29","author":"O Suzuki","year":"1980","unstructured":"Suzuki O, Hattori H, Asano M, Oya M, Katsumata Y (1980) Inhibition of monoamine oxidase by d-methamphetamine. Biochem Pharmacol 29(14):2071\u20132073. https:\/\/doi.org\/10.1016\/0006-2952(80)90493-1","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"6959_CR36","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/hc3301.094533","volume":"104","author":"JE Tcheng","year":"2001","unstructured":"Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, Cines DB, Jordan RE, Mascelli MA, Langrall MA, Damaraju L, Schantz A, Effron MB, Braden GA, Investigators, for the R. R. R (2001) Abciximab readministration. Circulation 104(8):870\u2013875. https:\/\/doi.org\/10.1161\/hc3301.094533","journal-title":"Circulation"},{"key":"6959_CR37","unstructured":"US Food and Drug Administration. Fact sheet for health care providers: Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab).\u00a0(n.d.). https:\/\/bit.ly\/3IWpQjg"},{"issue":"1","key":"6959_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/btt.s1374","volume":"2","author":"M Valgimigli","year":"2008","unstructured":"Valgimigli M, Campo G, Tebaldi M, Carletti R, Arcozzi C, Ferrari R, Percoco G (2008) Abciximab: a reappraisal of its use in coronary care. Biologics Targets Ther 2(1):29\u201339. https:\/\/doi.org\/10.2147\/btt.s1374","journal-title":"Biologics Targets Ther"},{"key":"6959_CR39","doi-asserted-by":"publisher","DOI":"10.1177\/1756283x17750355","volume":"11","author":"S Vermeire","year":"2018","unstructured":"Vermeire S, Gils A, Accossato P, Lula S, Marren A (2018) Immunogenicity of biologics in inflammatory bowel disease. Ther Adv Gastroenterol 11:1756283X17750355. https:\/\/doi.org\/10.1177\/1756283x17750355","journal-title":"Ther Adv Gastroenterol"},{"issue":"50","key":"6959_CR40","doi-asserted-by":"publisher","first-page":"29732","DOI":"10.1074\/jbc.m115.692434","volume":"290","author":"DB Yadav","year":"2015","unstructured":"Yadav DB, Sharma VK, Boswell CA, Hotzel I, Tesar D, Shang Y, Ying Y, Fischer SK, Grogan JL, Chiang EY, Urban K, Ulufatu S, Khawli LA, Prabhu S, Joseph S, Kelley RF (2015) Evaluating the use of antibody variable region (Fv) charge as a risk assessment tool for predicting typical cynomolgus monkey pharmacokinetics*. J Biol Chem 290(50):29732\u201329741. https:\/\/doi.org\/10.1074\/jbc.m115.692434","journal-title":"J Biol Chem"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06959-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06959-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06959-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:01:46Z","timestamp":1790197306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-025-06959-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["6959"],"URL":"https:\/\/doi.org\/10.1007\/s00213-025-06959-9","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Guide for the Care and Use of Laboratory Animals and with prior approval by the UAMS Institutional Animal Care and Use Committee.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors, Catalent Pharma Solutions, and Curia Bio, Inc. f\/k\/a LakePharma, Inc. have consented to the submission of this manuscript in its final form for publication.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stevens MW serves as Chief Operating Officer, Gentry WB serves as Chief Medical Officer, and Henry RL serves as Vice President of Biopharmaceutics for InterveXion Therapeutics, LLC (Little Rock, AR, USA), a pharmaceutical biotechnology company focused on treating substance use disorders with antibody-based therapy.","order":4,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}